By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ultragenyx Pharmaceuticals 

77 Digital Drive
Suite 210
Novato  California  94949  U.S.A.
Phone: 415-884-0223 Fax: 415-884-0562



Company News
Ultragenyx (RARE) Reports Second Quarter 2017 Financial Results and Corporate Update 7/28/2017 10:44:58 AM
Ultragenyx (RARE) Provides Regulatory Update On Burosumab (KRN23) 6/23/2017 8:32:14 AM
Ultragenyx (RARE) Announces Recombinant Human Beta-Glucuronidase Biologics License Application And Marketing Authorization Application Filed And Accepted For Review; FDA Grants Priority Review Status 5/23/2017 10:22:22 AM
Ultragenyx (RARE) Reports First Quarter 2017 Financial Results And Corporate Update 5/5/2017 11:35:44 AM
Ultragenyx (RARE) To Host Conference Call For First Quarter 2017 Financial Results And Corporate Update 5/1/2017 11:58:47 AM
Ultragenyx (RARE) Initiates Global Phase III Study Of UX007 In Glut1 DS Patients With Disabling Movement Disorders 4/27/2017 9:05:46 AM
Ultragenyx (RARE), Kyowa Hakko Kirin And Kyowa Kirin International Announce Positive 24-Week Data From Adult Phase II Study Of Burosumab (KRN23) In X-Linked Hypophosphatemia 4/19/2017 10:39:10 AM
Ultragenyx (RARE) Appoints Deborah Dunsire, M.D., To Board Of Directors 4/10/2017 10:38:57 AM
Bay Area's Ultragenyx (RARE) Tanks as Seizure Drug Flunks Phase II Test 3/23/2017 5:43:08 AM
Bay Area's Ultragenyx (RARE) Shelves Plan for a Quick Approval for Rare Disease Drug in Europe 11/11/2016 7:00:36 AM